title: A triterpenoid from Thalictrum fortunei induces apoptosis in BEL-7402 cells through the P53-induced apoptosis pathway.
abstract: Thalictrum fortunei S. Moore, a perennial plant distributed in the southeastern part of China, has been used in Traditional Chinese Medicine for thousands of years for its antitumor, antibacterial and immunoregulatory effects. In order to investigate the active components and the mechanism of the anti-tumor effects of Thalictrum fortunei, the growth inhibitory effects of eight triterpenoids isolated from the aerial parts of the plant on tumor cell lines were examined by 3-(4,5)-dimethylthiazoy1-3,5-diphenyltetrazolium bromide (MTT) assay. The MTT-assay results showed that the inhibitory activity of 3-O-β-D-glucopyranosyl-(1→4)-β-D-fucopyranosyl(22S,24Z)-cycloart-24-en-3β,22,26-triol 26-O-β-D-glucopyranoside (1) was stronger than that of the other seven tested triterpenoids on human hepatoma Bel-7402 cell line (Bel-7402), human colon lovo cells (LoVo), human non-small cells lung cancer NCIH-460 cells (NCIH-460) and human gastric carcinoma SGC-7901 cells (SGC-7901) after 48 h treatment in vitro, with the IC(50) values of 66.4, 84.8, 73.5, 89.6 μM, respectively. Moreover, the antitumor mechanism of compound 1 on Bel-7402 cell was explored through nucleus dyeing, fluorescence assay, flow cytometry and western blot. The flow cytometric analysis results revealed that compound 1 caused apoptosis and mitochondrial membrane potential (MMP) loss in Bel-7402 cells. A fluorescence assay indicated that intracellular reactive oxygen species (ROS) were markedly provoked by compound 1 treatment compared to control cells. Immunoblot results showed that compound 1 significantly increased the expression levels of cleaved caspase-3, P53 and Bax protein, and decreased the expression level of Bcl-2 protein. These findings indicate that compound 1 inhibits the growth activity of tumor cells, probably through the P53 protein-induced apoptosis pathway.
authors.affiliation: Guangdong Research Institute of Traditional Chinese Medicine, Guangzhou, China.
authors.forename: Xiantao
authors.initials: X
authors.lastname: Zhang
authors.forename: Ming
authors.initials: M
authors.lastname: Zhao
authors.forename: Lvyi
authors.initials: L
authors.lastname: Chen
authors.forename: Haoyan
authors.initials: H
authors.lastname: Jiao
authors.forename: Hongxia
authors.initials: H
authors.lastname: Liu
authors.forename: Liyan
authors.initials: L
authors.lastname: Wang
authors.forename: Shuwei
authors.initials: S
authors.lastname: Ma
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor / Q000187:drug effects*; D006801:Humans; D020128:Inhibitory Concentration 50; D008516:Medicine, Chinese Traditional; D053078:Membrane Potential, Mitochondrial / Q000187:drug effects; D015394:Molecular Structure; D010936:Plant Extracts / Q000737:chemistry / Q000494:pharmacology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D031949:Thalictrum / Q000737:chemistry*; D014315:Triterpenes / Q000737:chemistry / Q000494:pharmacology; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D051028:bcl-2-Associated X Protein / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D010936:Plant Extracts; D019253:Proto-Oncogene Proteins c-bcl-2; D017382:Reactive Oxygen Species; D014315:Triterpenes; D016159:Tumor Suppressor Protein p53; D051028:bcl-2-Associated X Protein; D053148:Caspase 3
references.citation: Nat Cell Biol. 2002 Nov;4(11):842-9
references.pmid: 12402042
references.citation: Neurochem Int. 2010 Oct;57(3):206-15
references.pmid: 20510317
references.citation: Molecules. 2011 Aug 23;16(8):7155-70
references.pmid: 21862957
references.citation: Mol Vis. 2011;17:1987-96
references.pmid: 21850173
references.citation: J Med Chem. 2005 May 5;48(9):3410-6
references.pmid: 15857147
references.citation: J Biol Chem. 2011 Jun 3;286(22):20087-99
references.pmid: 21467033
references.citation: Chem Pharm Bull (Tokyo). 2006 Jan;54(1):107-10
references.pmid: 16394560
references.citation: Expert Opin Emerg Drugs. 2006 Sep;11(3):469-87
references.pmid: 16939386
references.citation: J Breast Cancer. 2011 Mar;14(1):8-13
references.pmid: 21847388
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078
references.citation: Pharmacol Rep. 2011;63(3):724-32
references.pmid: 21857083
references.citation: Science. 2004 Feb 13;303(5660):1010-4
references.pmid: 14963330
references.citation: Cell. 2006 Jul 14;126(1):107-20
references.pmid: 16839880
references.citation: Biol Pharm Bull. 2010;33(8):1274-8
references.pmid: 20686218
references.citation: Mol Cell. 2003 Mar;11(3):577-90
references.pmid: 12667443
references.citation: Nanoscale Res Lett. 2011 Jul 29;6:480
references.pmid: 21801413
references.citation: Cytotechnology. 2010 Oct;62(5):449-60
references.pmid: 20842425
references.citation: Chem Pharm Bull (Tokyo). 2011;59(3):338-40
references.pmid: 21372415
references.citation: Acta Pharmacol Sin. 2011 Aug;32(8):1025-30
references.pmid: 21765447
references.citation: Biol Pharm Bull. 2010;33(8):1343-8
references.pmid: 20686229
references.citation: Biol Pharm Bull. 2008 Apr;31(4):592-7
references.pmid: 18379047
references.citation: Adv Exp Med Biol. 2008;615:201-21
references.pmid: 18441595
references.citation: Science. 2004 Jul 30;305(5684):626-9
references.pmid: 15286356